Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Discontinuation for Patients With Giant Cell Arteritis in Remission
NCT07108387Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in giant cell arteritis (GCA), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2026; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT07108387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108387.